VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Summary

This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Timeline

Start

2011-07

Primary completion

2011-11

Completion

2012-10

Drugs

Indications